Search research articles
Contact Us
Filters
Showing results (81-90 of 106) with videos related to
Page
of 11
Sort By:
American Journal of Preventive Cardiology
|
July 30, 2021
Synopsis of an integrated guidance for enhancing the care of familial hypercholesterolaemia: an Australian perspective
Gerald F Watts, David R Sullivan, David L Hare, et al.
International Journal of Cardiology
|
August 31, 2015
Biomarkers in stable coronary heart disease, their modulation and cardiovascular risk: The LIPID biomarker study
Andrew M Tonkin, Stefan Blankenberg, Adrienne Kirby, et al.
Internal Medicine Journal
|
May 28, 2021
Essentials of a new clinical practice guidance on familial hypercholesterolaemia for physicians
Gerald F Watts, David R Sullivan, David L Hare, et al.
American Journal of Preventive Cardiology
|
April 11, 2022
Corrigendum to Synopsis of an integrated guidance for enhancing the care of familial hypercholesterolaemia: An Australian perspective [American Journal of Preventive Cardiology 6 (2021) 100151]
Gerald F Watts, David R Sullivan, David L Hare, et al.
The Lancet. Diabetes & Endocrinology
|
December 21, 2025
Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial
Frederick J Raal, Jean Bergeron, Daniel Gaudet, et al.
Circulation
|
March 27, 2016
Long-Term Effectiveness and Safety of Pravastatin in Patients With Coronary Heart Disease: Sixteen Years of Follow-Up of the LIPID Study
Wendy E Hague, John Simes, Adrienne Kirby, et al.
Metabolism: Clinical and Experimental
|
April 18, 2016
Opposite associations between alanine aminotransferase and γ-glutamyl transferase levels and all-cause mortality in type 2 diabetes: Analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
Kathryn H Williams, David R Sullivan, Geoffrey C Nicholson, et al.
Clinical Chemistry
|
June 14, 2017
Baseline Circulating FGF21 Concentrations and Increase after Fenofibrate Treatment Predict More Rapid Glycemic Progression in Type 2 Diabetes: Results from the FIELD Study
Kwok-Leung Ong, Rachel O'Connell, Andrzej S Januszewski, et al.
Journal of Diabetes and Its Complications
|
April 22, 2026
Unveiling novel biomarkers for diabetes-related complications through large-scale proteomics analysis: A FIELD sub-study
Habib Francis, Andrzej S Januszewski, Matthew B O'Rourke, et al.
Heart, Lung & Circulation
|
January 8, 2026
Corrigendum to: "Australian Atherosclerosis Society Position Statement on Lipoprotein(a): Clinical and Implementation Recommendations" [Heart Lung Circ. 32(3) (2023) 287-296.]
Natalie C Ward, Gerald F Watts, Warrick Bishop, et al.
Page
of 11
Search research articles
Search
Showing results (81-90 of 106) with videos related to
Sort By:
Page
of 11
American Journal of Preventive Cardiology
|
July 30, 2021
Synopsis of an integrated guidance for enhancing the care of familial hypercholesterolaemia: an Australian perspective
Gerald F Watts, David R Sullivan, David L Hare, et al.
International Journal of Cardiology
|
August 31, 2015
Biomarkers in stable coronary heart disease, their modulation and cardiovascular risk: The LIPID biomarker study
Andrew M Tonkin, Stefan Blankenberg, Adrienne Kirby, et al.
Internal Medicine Journal
|
May 28, 2021
Essentials of a new clinical practice guidance on familial hypercholesterolaemia for physicians
Gerald F Watts, David R Sullivan, David L Hare, et al.
American Journal of Preventive Cardiology
|
April 11, 2022
Corrigendum to Synopsis of an integrated guidance for enhancing the care of familial hypercholesterolaemia: An Australian perspective [American Journal of Preventive Cardiology 6 (2021) 100151]
Gerald F Watts, David R Sullivan, David L Hare, et al.
The Lancet. Diabetes & Endocrinology
|
December 21, 2025
Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial
Frederick J Raal, Jean Bergeron, Daniel Gaudet, et al.
Circulation
|
March 27, 2016
Long-Term Effectiveness and Safety of Pravastatin in Patients With Coronary Heart Disease: Sixteen Years of Follow-Up of the LIPID Study
Wendy E Hague, John Simes, Adrienne Kirby, et al.
Metabolism: Clinical and Experimental
|
April 18, 2016
Opposite associations between alanine aminotransferase and γ-glutamyl transferase levels and all-cause mortality in type 2 diabetes: Analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
Kathryn H Williams, David R Sullivan, Geoffrey C Nicholson, et al.
Clinical Chemistry
|
June 14, 2017
Baseline Circulating FGF21 Concentrations and Increase after Fenofibrate Treatment Predict More Rapid Glycemic Progression in Type 2 Diabetes: Results from the FIELD Study
Kwok-Leung Ong, Rachel O'Connell, Andrzej S Januszewski, et al.
Journal of Diabetes and Its Complications
|
April 22, 2026
Unveiling novel biomarkers for diabetes-related complications through large-scale proteomics analysis: A FIELD sub-study
Habib Francis, Andrzej S Januszewski, Matthew B O'Rourke, et al.
Heart, Lung & Circulation
|
January 8, 2026
Corrigendum to: "Australian Atherosclerosis Society Position Statement on Lipoprotein(a): Clinical and Implementation Recommendations" [Heart Lung Circ. 32(3) (2023) 287-296.]
Natalie C Ward, Gerald F Watts, Warrick Bishop, et al.
Page
of 11